Enzon Pharmaceuticals, Inc. (ENZN) Reports Q4 Loss of $0.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts ENZN Hot Sheet
Price: $4.35 --0%
Financial Fact:
Income tax expense (benefit): 5.27M
Today's EPS Names:
HOVR, VFS, PGR, More
Financial Fact:
Income tax expense (benefit): 5.27M
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) reported Q4 EPS of ($0.10), versus ($0.16) reported last year. Revenue from royalties for the quarter came in at $9.8 million, versus $10.6 million reported last year.
For earnings history and earnings-related data on Enzon Pharmaceuticals, Inc. (ENZN) click here.
For earnings history and earnings-related data on Enzon Pharmaceuticals, Inc. (ENZN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top AI Semiconductor Stocks According to Stifel Analysis
- Marathon Petroleum (MPC) PT Raised to $510 at UBS
- Amrize Ltd (AMRZ) PT Lowered to $40 at DA Davidson as FY26 Guidance 'at Risk'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
